Pediatric epilepsy surgery: long-term 5-year seizure remission and medication use

Jason S Hauptman1, Kayvon Pedram, Christia Angela Sison

  • 1Department of Neurosurgery, Mattel Children's Hospital, David Geffen School of Medicine, University of California, Los Angeles, California, USA.

Neurosurgery
|August 17, 2012
PubMed

Insights

Pediatric epilepsy surgery outcomes show improvement over 20 years, with over half of patients remaining seizure-free long-term. These results mirror adult epilepsy surgery outcomes, indicating successful treatment for children.

Area of Science:

  • Pediatric Neurology
  • Neurosurgery
  • Epileptology

Background:

  • Long-term seizure outcomes in pediatric epilepsy surgery patients remain incompletely understood compared to adults.
  • Variability in outcomes necessitates investigation into factors influencing seizure control and medication use post-surgery in children.

Purpose of the Study:

  • To evaluate 5-year seizure outcomes and antiepilepsy drug (AED) usage in pediatric epilepsy surgery patients.
  • To compare outcomes across different surgical periods and etiological factors in children undergoing epilepsy surgery.

Main Methods:

  • Retrospective analysis of pediatric epilepsy surgery patients (under 18) with available 5-year outcome data by 2010.
  • Comparison of seizure-free rates, late recurrence, and AED discontinuation based on surgical era, etiology, and resection type.

Main Results:

  • 53% of pediatric patients with 5-year data achieved continuous seizure freedom; 18% experienced late recurrence.
  • Continuously seizure-free rates improved significantly with surgeries performed between 2001-2005 (68%) compared to earlier periods.
  • 55% of continuously seizure-free patients discontinued antiepilepsy drugs (AEDs), with higher rates in cortical dysplasia cases.

Conclusions:

  • Pediatric epilepsy surgery outcomes have improved over two decades, demonstrating enhanced clinical experience.
  • Achieved 5-year seizure control in children is comparable to adult epilepsy surgery patients, even with diverse etiologies and extratemporal/hemispheric operations.
Abstract

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Epilepsy ll: Types01:22

Epilepsy ll: Types

Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...